TY - JOUR
T1 - Lymphomatoid papulosis
T2 - Treatment response and associated lymphomas in a study of 180 patients
AU - Wieser, Iris
AU - Oh, Chee Won
AU - Talpur, Rakhshandra
AU - Duvic, Madeleine
N1 - Publisher Copyright:
© 2015 by the American Academy of Dermatology, Inc.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Background Lymphomatoid papulosis (LyP) is a CD30+ lymphoproliferative disorder, with a self-regressing clinical course and malignant histopathology. Objective The aim of this study was to evaluate characteristics, risk factors, associated malignancies, long-term outcome, and treatment of LyP in a large cohort representing the experience of the MD Anderson Cancer Center. Methods Patient charts and clinical and histopathologic data of 180 patients with LyP were retrospectively assessed. Results A total of 56.7% of patients was men. Histologic subtype A was found in 47.2%, type B in 17.2%, type C in 22.8%, type D in 7.8%, type E in 0.6%, and mixed subtype in 4.4% of the patients. One hundred fourteen lymphomas were observed in 93 patients, with mycosis fungoides (61.4%) and anaplastic large cell lymphoma (26.3%) being the most common forms. Risk factors for development of lymphoma included sex and histologic subtype. Number of lesions and symptom severity were not associated with lymphoma development. Patients with type D were less likely to have lymphomas. Treatment provided symptomatic relief but did not prevent progression to lymphoma. Limitations The limitation of this study is the retrospective study design. Conclusion Patients with LyP are at increased risk of associated lymphomas. Thorough patient counseling is needed and long follow-up periods are required to detect and treat secondary lymphomas.
AB - Background Lymphomatoid papulosis (LyP) is a CD30+ lymphoproliferative disorder, with a self-regressing clinical course and malignant histopathology. Objective The aim of this study was to evaluate characteristics, risk factors, associated malignancies, long-term outcome, and treatment of LyP in a large cohort representing the experience of the MD Anderson Cancer Center. Methods Patient charts and clinical and histopathologic data of 180 patients with LyP were retrospectively assessed. Results A total of 56.7% of patients was men. Histologic subtype A was found in 47.2%, type B in 17.2%, type C in 22.8%, type D in 7.8%, type E in 0.6%, and mixed subtype in 4.4% of the patients. One hundred fourteen lymphomas were observed in 93 patients, with mycosis fungoides (61.4%) and anaplastic large cell lymphoma (26.3%) being the most common forms. Risk factors for development of lymphoma included sex and histologic subtype. Number of lesions and symptom severity were not associated with lymphoma development. Patients with type D were less likely to have lymphomas. Treatment provided symptomatic relief but did not prevent progression to lymphoma. Limitations The limitation of this study is the retrospective study design. Conclusion Patients with LyP are at increased risk of associated lymphomas. Thorough patient counseling is needed and long follow-up periods are required to detect and treat secondary lymphomas.
KW - CD30 lymphoproliferative disorders
KW - associated lymphomas
KW - cutaneous T-cell lymphoma
KW - lymphomatoid papulosis
KW - lymphomatoid papulosis treatment
UR - http://www.scopus.com/inward/record.url?scp=84953638039&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84953638039&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2015.09.013
DO - 10.1016/j.jaad.2015.09.013
M3 - Article
C2 - 26518172
AN - SCOPUS:84953638039
SN - 0190-9622
VL - 74
SP - 59
EP - 67
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 1
ER -